spacer
home > pmps > spring 2019 > the impact of falsified medicines
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Impact of Falsified Medicines

In recent years, the number of falsified and counterfeit medications infiltrating the supply chain has become a growing problem for global health organisations and pharmaceutical manufacturers. Not only have there been cost implications, but there are also huge risks to patient safety.

The WHO references illegitimate medications as substandard and falsified medical products, with falsified medicines defined as “medical products that deliberately/ fraudulently misrepresent their identity, composition, or source” (1).

According to the WHO, about one in 10 pharmaceutical products in low and middle income countries are either substandard or falsified (2). The WHO also reported that, as of November 2017, “20 global medical product alerts and numerous regional warnings” had been issued, with “technical support provided in more than 100 cases” (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Neil Piper is an Auto ID expert and business consultant with over 25 years’ experience working predominantly in the retail and healthcare sectors. He is skilled in GS1 International Society of Blood Transfusion standards, barcode technologies (printing and scanning), radio frequency identification, electronic product code information services, and regulatory compliance (FMD, unique device identification, both FDA and EU medical devices regulation/in vitro diagnostic medical devices, UK Medicines and Healthcare products Regulatory Agency GS1 compliance, and more). Neil is currently redrafting Information Standards Board (ISB) 1077 and ISB 0108 standards to comply with NHS digital requirements. He has provided consultancy to numerous NHS trusts and pharmaceutical and medical device suppliers.
spacer
Neil Piper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement